Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma
Abstract We evaluated the predictive role of circulating tumor DNA (ctDNA) detection by targeted deep sequencing in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint blockades (ICB). To determine the feasibility of ctDNA detection in our panel encompassing 40 genes,...
Guardado en:
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5919a4ecc5f74b4eb3508a869b37d47b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:5919a4ecc5f74b4eb3508a869b37d47b |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:5919a4ecc5f74b4eb3508a869b37d47b2021-12-02T13:34:46ZPotential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma10.1038/s41598-021-85099-42045-2322https://doaj.org/article/5919a4ecc5f74b4eb3508a869b37d47b2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85099-4https://doaj.org/toc/2045-2322Abstract We evaluated the predictive role of circulating tumor DNA (ctDNA) detection by targeted deep sequencing in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint blockades (ICB). To determine the feasibility of ctDNA detection in our panel encompassing 40 genes, we collected 10 ml of blood from 20 patients at the time of radical nephrectomy. We analyzed somatic mutations in primary tumors and ctDNA samples from these patients. We finally collected 10 ml of blood before and after 1 month of treatment, respectively, from four patients with mRCC who received first-line ICB treatment. Variants were detected in primary tumors of 15 patients (75%) and ctDNA was detected in the plasma of 9 patients (45%). We examined the predictive role of ctDNA in four patients who received first-line ICB therapy. In two patients showing partial response, ctDNA levels decreased after 1 month of ICB treatment. However, in one patient who showed disease progression, ctDNA levels increased after 1 month of ICB treatment. Taken together, ctDNA detection in plasma by targeted deep sequencing was feasible in patients with RCC. Moreover, the levels of ctDNA could be an early predictor of treatment response in patients with mRCC who receive ICB therapy.Yeon Jeong KimYumi KangJun Seop KimHyun Hwan SungHwang Gyun JeonByong Chang JeongSeong Il SeoSeong Soo JeonHyun Moo LeeDonghyun ParkWoong-Yang ParkMinyong KangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Medicine R Science Q |
spellingShingle |
Medicine R Science Q Yeon Jeong Kim Yumi Kang Jun Seop Kim Hyun Hwan Sung Hwang Gyun Jeon Byong Chang Jeong Seong Il Seo Seong Soo Jeon Hyun Moo Lee Donghyun Park Woong-Yang Park Minyong Kang Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma |
description |
Abstract We evaluated the predictive role of circulating tumor DNA (ctDNA) detection by targeted deep sequencing in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint blockades (ICB). To determine the feasibility of ctDNA detection in our panel encompassing 40 genes, we collected 10 ml of blood from 20 patients at the time of radical nephrectomy. We analyzed somatic mutations in primary tumors and ctDNA samples from these patients. We finally collected 10 ml of blood before and after 1 month of treatment, respectively, from four patients with mRCC who received first-line ICB treatment. Variants were detected in primary tumors of 15 patients (75%) and ctDNA was detected in the plasma of 9 patients (45%). We examined the predictive role of ctDNA in four patients who received first-line ICB therapy. In two patients showing partial response, ctDNA levels decreased after 1 month of ICB treatment. However, in one patient who showed disease progression, ctDNA levels increased after 1 month of ICB treatment. Taken together, ctDNA detection in plasma by targeted deep sequencing was feasible in patients with RCC. Moreover, the levels of ctDNA could be an early predictor of treatment response in patients with mRCC who receive ICB therapy. |
format |
article |
author |
Yeon Jeong Kim Yumi Kang Jun Seop Kim Hyun Hwan Sung Hwang Gyun Jeon Byong Chang Jeong Seong Il Seo Seong Soo Jeon Hyun Moo Lee Donghyun Park Woong-Yang Park Minyong Kang |
author_facet |
Yeon Jeong Kim Yumi Kang Jun Seop Kim Hyun Hwan Sung Hwang Gyun Jeon Byong Chang Jeong Seong Il Seo Seong Soo Jeon Hyun Moo Lee Donghyun Park Woong-Yang Park Minyong Kang |
author_sort |
Yeon Jeong Kim |
title |
Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma |
title_short |
Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma |
title_full |
Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma |
title_fullStr |
Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma |
title_full_unstemmed |
Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma |
title_sort |
potential of circulating tumor dna as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma |
publisher |
Nature Portfolio |
publishDate |
2021 |
url |
https://doaj.org/article/5919a4ecc5f74b4eb3508a869b37d47b |
work_keys_str_mv |
AT yeonjeongkim potentialofcirculatingtumordnaasapredictoroftherapeuticresponsestoimmunecheckpointblockadesinmetastaticrenalcellcarcinoma AT yumikang potentialofcirculatingtumordnaasapredictoroftherapeuticresponsestoimmunecheckpointblockadesinmetastaticrenalcellcarcinoma AT junseopkim potentialofcirculatingtumordnaasapredictoroftherapeuticresponsestoimmunecheckpointblockadesinmetastaticrenalcellcarcinoma AT hyunhwansung potentialofcirculatingtumordnaasapredictoroftherapeuticresponsestoimmunecheckpointblockadesinmetastaticrenalcellcarcinoma AT hwanggyunjeon potentialofcirculatingtumordnaasapredictoroftherapeuticresponsestoimmunecheckpointblockadesinmetastaticrenalcellcarcinoma AT byongchangjeong potentialofcirculatingtumordnaasapredictoroftherapeuticresponsestoimmunecheckpointblockadesinmetastaticrenalcellcarcinoma AT seongilseo potentialofcirculatingtumordnaasapredictoroftherapeuticresponsestoimmunecheckpointblockadesinmetastaticrenalcellcarcinoma AT seongsoojeon potentialofcirculatingtumordnaasapredictoroftherapeuticresponsestoimmunecheckpointblockadesinmetastaticrenalcellcarcinoma AT hyunmoolee potentialofcirculatingtumordnaasapredictoroftherapeuticresponsestoimmunecheckpointblockadesinmetastaticrenalcellcarcinoma AT donghyunpark potentialofcirculatingtumordnaasapredictoroftherapeuticresponsestoimmunecheckpointblockadesinmetastaticrenalcellcarcinoma AT woongyangpark potentialofcirculatingtumordnaasapredictoroftherapeuticresponsestoimmunecheckpointblockadesinmetastaticrenalcellcarcinoma AT minyongkang potentialofcirculatingtumordnaasapredictoroftherapeuticresponsestoimmunecheckpointblockadesinmetastaticrenalcellcarcinoma |
_version_ |
1718392736357285888 |